Profile

Cover photo
5 followers|15,866 views
AboutPostsPhotosVideos

Stream

InSite Vision

Shared publicly  - 
 
InSite Announces Court Judgment Upholding All AzaSite Patents in Patent Infringement Lawsuit Against Sandoz Inc. http://bit.ly/18JQqFo
Printer Friendly Version View printer-friendly version. << Back. InSite Vision Announces Court Judgment Upholding All AzaSite® Patents in Patent Infringement Lawsuit Against Sandoz Inc. ALAMEDA, Calif. --(BUSINESS WIRE)--Oct. 7, 2013-- InSite Vision Incorporated (OTCBB: INSV) today announced ...
1
Add a comment...

InSite Vision

Shared publicly  - 
 
InSite Vision Reports Second Quarter 2013 Financial Results http://bit.ly/17a6deq
InSite Vision Reports Second Quarter 2013 Financial Results. ALAMEDA, Calif. --(BUSINESS WIRE)--Aug. 8, 2013-- InSite Vision Incorporated (OTCBB: INSV) today reported financial results for the quarter ended June 30, 2013 . Revenues for the second quarter of 2013 were $19.2 million compared to ...
1
Add a comment...

InSite Vision

Shared publicly  - 
 
Our CEO, Tim Ruane, will be presenting at the 8th Annual JMP Securities Healthcare Conference on July 9th at 12pm ET. Learn more: http://bit.ly/15dnbtG
InSite Vision to Present at the 8th Annual JMP Securities Healthcare Conference. ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 2, 2013-- InSite Vision Incorporated (OTCBB: INSV) today announced that Timothy Ruane , InSite's Chief Executive Officer, will be presenting at the 8th Annual JMP Securities ...
1
Add a comment...

InSite Vision

Shared publicly  - 
 
We announced that we have regained North American development rights to azithromycin ophthalmic solution 2%, trademarked as AzaSite Xtra™. Learn more about our latest news and read the comments from our CEO, Tim Ruane. http://bit.ly/14NZJmA
InSite Vision Regains Development Rights for AzaSite Xtra™. Potential Product to Extend AzaSite® Ophthalmology Franchise Through 2027 and Beyond. ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 21, 2013-- InSite Vision Incorporated (OTCBB: INSV) today announced that the company has regained North ...
1
Add a comment...

InSite Vision

Shared publicly  - 
 
We have begun patient enrollment for the confirmatory Phase 3 clinical trial of BromSite™ for the treatment of inflammation and pain after cataract surgery. InSite Vision is looking to enroll approximately 240 patients. The study design is identical in design to the first prior successful Phase 3 study. Learn more in our recent press release: 
Printer Friendly Version View printer-friendly version. << Back. InSite Vision Initiates Confirmatory Phase 3 Clinical Study of BromSite™ for the Reduction of Inflammation and Pain after Cataract Surgery. ALAMEDA, Calif. --(BUSINESS WIRE)--May. 9, 2013-- InSite Vision Incorporated (OTCBB: INSV) ...
1
Add a comment...

InSite Vision

Shared publicly  - 
 
Today we announced that InSite Vision will present five scientific posters at the 2013 Association for Research in Vision and Ophthalmology Annual Meeting from May 5th-9th in Seattle. The presentation schedule is available in our press release.
InSite Vision to Present Five Scientific Posters at 2013 ARVO Meeting. ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 29, 2013-- InSite Vision Incorporated (OTCBB: INSV) today announced that it has sponsored...
1
Add a comment...
Have them in circles
5 people
Hampton & Associates's profile photo
ICOM Mechanical Inc.'s profile photo
Ashley DeSimone's profile photo
Jonah Samuels's profile photo
Liz Peters's profile photo

InSite Vision

Shared publicly  - 
 
Today we announced that the USPTO has issued a patent on DuraSite® 2 which will provide protection to 2029 for both the delivery system and the drugs that are formulated with DuraSite® 2. Learn more: http://bit.ly/16SvQlY
Printer Friendly Version View printer-friendly version. << Back. InSite Vision Announces Patent Issuance on DuraSite® 2 Ophthalmic Drug Delivery System. New Therapeutics Formulated in Novel Platform Technology Will Have Patent Protection to 2029 for Internal Pipeline and Partnering ...
1
Add a comment...

InSite Vision

Shared publicly  - 
 
InSite Vision to Report Second Quarter 2013 Financial Results on August 8, 2013 http://bit.ly/16dnRNL
InSite Vision to Report Second Quarter 2013 Financial Results on August 8, 2013. ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 25, 2013-- InSite Vision Incorporated (OTCBB: INSV) announced today that it will report financial results for the second quarter ended June 30, 2013 on Thursday, August 8, ...
1
Add a comment...

InSite Vision

Shared publicly  - 
 
Today we announced that we have received a Notice of Allowance from the United States Patent and Trademark Office for patent on DuraSite 2 ophthalmic drug delivery system. The patent is expected to provide protection to 2029 for DuraSite 2 and drugs formulated with DuraSite 2. Learn more and read the comments from our CEO, Tim Ruane, in today’s press release. http://bit.ly/15dklVA
InSite Vision Receives Notice of Allowance from USPTO for Patent on DuraSite® 2 Ophthalmic Drug Delivery System. New Therapeutics Formulated in Novel Platform Technology Expected to Have Patent Protection to 2029 for Internal Pipeline and Partnering. ALAMEDA, Calif. --(BUSINESS WIRE)--Jul.
1
Add a comment...

InSite Vision

Shared publicly  - 
 
We are joining Merck (NYSE:MRK) and Pfizer (NYSE:PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals who recently filed an ANDA to market a generic version of AzaSite®. Merck will take the lead and InSite Vision (OTCBB:INSV) will assume a monitoring role. The trial date for a similar lawsuit against Sandoz Inc. has been set for July 11th, 2013. http://bit.ly/13UbxB8
InSite Vision Announces Joint Patent Infringement Lawsuit with Merck Against Mylan Pharmaceuticals. Company Also Provides Update on Sandoz ANDA/Paragraph IV Trial Date. ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 17, 2013-- InSite Vision Incorporated (OTCBB:INSV) today announced that it will join ...
1
Add a comment...

InSite Vision

Shared publicly  - 
 
We will report our financial results for the first quarter ended March 31, 2013 on Tuesday, May 7, 2013. Our management will be holding a conference call on the same day at 4:30pm ET/1:30pm PT to discuss the results. Get the details here: 
Printer Friendly Version View printer-friendly version. << Back. InSite Vision to Report First Quarter 2013 Financial Results on May 7, 2013. ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 29, 2013-- I...
1
Add a comment...

InSite Vision

Shared publicly  - 
 
Today we announced our new agreement to sell Besivance royalty to SWK Funding LLC and its partner Bess Royalty, LP for $15 million at closing with a further $1 million payable in early 2014. According to our CEO, Tim Ruane, the agreement enables InSite Vision to provide a non-dilutive source of cash for the company’s operations. Learn more in today’s press release: 
InSite Vision Announces Sale of Besivance® Royalty for $15 Million Plus a $1 Million Potential Milestone in Early 2014. The Royalty May Be Returned to InSite Vision In Whole or In Part If the Buyers R...
1
Add a comment...
People
Have them in circles
5 people
Hampton & Associates's profile photo
ICOM Mechanical Inc.'s profile photo
Ashley DeSimone's profile photo
Jonah Samuels's profile photo
Liz Peters's profile photo
Contact Information
Contact info
Phone
510.865.8800
Fax
510.865.5700
Address
965 Atlantic Avenue Alameda, CA 94501
Story
Tagline
Solutions for Sight
Introduction
InSite Vision develops ophthalmic products designed to treat a growing range of common eye problems and strives to preserve and improve vision worldwide.